Neonc Technologies Holdings Inc (NTHI)

$12.00 -0.11 (-0.91%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 9,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Latest News on NTHI

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 27, 2025, 8:05 AM EDT - 2 days ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:45 AM EDT - 4 days ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 4 days ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

Jan 4, 2025, 12:30 AM EST - 3 months ago

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

AERO CAPS CRGT FBGL FLOC INLF INR

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Oct 7, 2024, 11:00 AM EDT - 6 months ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Aug 5, 2024, 11:00 AM EDT - 8 months ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jul 16, 2024, 11:15 AM EDT - 9 months ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Jun 26, 2024, 4:39 PM EDT - 9 months ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

May 15, 2024, 11:00 AM EDT - 11 months ago

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

May 9, 2024, 5:30 PM EDT - 11 months ago

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

Mar 30, 2024, 1:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

BOLD MMA MNDR NTCL ROTR UBXG WAY

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

Dec 25, 2023, 9:05 AM EST - 1 year ago

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

LGCB MAMO LZMH

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

Dec 20, 2023, 2:38 PM EST - 1 year ago

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline